Bibliographic Details
| Title: |
Donepezil in the treatment of progressive supranuclear palsy. |
| Authors: |
Fabbrini, G., Barbanti, P., Bonifati, V., Colosimo, C., Gasparini, M., Vanacore, N., Meco, G. |
| Source: |
Acta Neurologica Scandinavica. Feb2001, Vol. 103 Issue 2, p123-125. 3p. |
| Subjects: |
Cholinesterase inhibitors, Progressive supranuclear palsy, Drug therapy |
| Abstract: |
Objectives – To evaluate the effect of 3 month therapy with donepezil, a centrally acting cholinesterase inhibitor, on cognitive performances, motor function and daily living activities in progressive supranuclear palsy (PSP). Materials and methods – Six patients with a diagnosis of PSP were evaluated at baseline and after 3 months of treatment with donepezil, 10 mg given at bedtime. Cognitive functions, motor symptoms and daily activities were evaluated by means of appropriate rating scales. Results – Donepezil was not effective on cognitive dysfunction and did not change ratings of daily living. Parkinsonian symptoms were unaffected by donepezil treatment. Conclusions – Cholinergic replacement therapy alone is not likely to improve symptoms in a disorder characterized by a more widespread impairment of monoaminergic systems. Larger studies may be necessary to confirm the lack of effect of donepezil in this disorder. [ABSTRACT FROM AUTHOR] |
|
Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Psychology and Behavioral Sciences Collection |
